Position in ELAN
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$8,414,601
+$2,868,728 QoQ
Shares Held
341,918
+47.5% QoQ
Ownership
0.068%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#94
of 518 holders
Holding Since
Sep 2020
23 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ELAN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026FIRST TRUST ADVISORS LP holds $670,557,120 across 30 Drug Manufacturers - Specialty & Generic names. ELAN ranks #10 (1.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
923,125 | $155,583,487 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
249,056 | $134,946,012 | |
| 3 | ALKS |
Alkermes plc.
|
2,421,016 | $126,861,238 | |
| 4 | ZTS |
Zoetis Inc.
|
1,435,652 | $103,165,952 | |
| 5 | TAK |
Takeda Pharmaceutical Co Ltd
|
2,114,912 | $33,902,039 | |
| 6 | LQDA |
Liquidia Corp
|
301,432 | $24,033,173 | |
| 7 | BCRX |
Biocryst Pharmaceuticals Inc
|
1,120,469 | $11,204,690 | |
| 8 | AMRX |
Amneal Pharmaceuticals, Inc.
|
614,206 | $10,631,905 |
All Filings in ELAN
Export CSV
23 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $8,414,601 | 341,918 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $5,545,873 | 231,754 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $23,981,011 | 1,059,700 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $35,109,840 | 1,743,289 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $35,711,738 | 2,500,822 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $19,165,912 | 1,825,325 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $1,611,090 | 133,038 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $321,343 | 21,875 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $2,149,435 | 148,956 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $513,682 | 31,553 | Shares | Sole | 2024-05-13 | |
| 2023-12-31 | $30,017,227 | 2,014,579 | Shares | Sole | 2024-02-13 | |
| 2023-09-30 | $30,512,519 | 2,714,637 | Shares | Sole | 2023-11-13 | |
| 2023-06-30 | $31,715,035 | 3,152,588 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $21,796,785 | 2,318,807 | Shares | Sole | 2023-05-15 | |
| 2022-12-31 | $19,698,371 | 1,611,978 | Shares | Sole | 2023-02-09 | |
| 2022-09-30 | $853,510 | 68,776 | Shares | Sole | 2022-11-14 | |
| 2022-06-30 | $5,113,811 | 260,510 | Shares | Sole | 2022-08-12 | |
| 2022-03-31 | $3,084,046 | 118,208 | Shares | Sole | 2022-05-13 | |
| 2021-09-30 | $16,524,313 | 518,166 | Shares | Sole | 2021-11-15 | |
| 2021-06-30 | $26,133,676 | 753,349 | Shares | Sole | 2021-10-12 | |
| 2021-03-31 | $7,900,610 | 268,272 | Shares | Sole | 2021-05-14 | |
| 2020-12-31 | $388,374 | 12,663 | Shares | Sole | 2021-02-02 | |
| 2020-09-30 | $218,636 | 7,828 | Shares | Sole | 2020-11-05 | |
| No filing history on record for this holder in this stock. | ||||||